Skip to main content

Table 4 Patient characteristics and parameters.

From: The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?

Parameter Total Group A (N = 10) Group B (N = 18) Group C (N = 19)
Gender     
Male 84% 100% 100% 68,7%
Female 16% 0% 0% 31,3%
HIV-1 subtype     
Patients with subtype B 69% 80% 64% 67%
Patients with non-B subtype 31% 20% 36% 33%
Treatment history     
Mean duration under ART in months (mean) 66 80 88 54
Current active drug score (mean) - 1.5 1.3 0.5
HIV-1 RNA [copies/ml; median]     
Baseline 20,163 26,950 8,800 42,600
CD4 cell counts [cells/μl; median]     
Baseline 260 291 307 246
  1. Patient characteristics and parameters. All patients were categorized in three groups as described throughout the article: Group A (ATV and or SQV), group B (ATV and or SQV plus L76V selecting drug LPV, APV or DRV) and group C (L76V selecting drug plus optimized backbone therapy).